Human respiratory syncytial virus cDNA and Antigen

Human respiratory syncytial virus (RSV) is a common respiratory virus that infects people of all ages but is most severe in young children, elderly individuals, and individuals with weakened immune systems. RSV causes respiratory symptoms such as cough, wheezing, and difficulty breathing, and in severe cases, it can lead to hospitalization and death. There is currently no specific treatment or cure for RSV, and management of the disease primarily involves relieving symptoms and providing supportive care. Vaccine development for RSV is an active area of research, and the development of an effective vaccine would have a significant impact on global public health.

The human respiratory syncytial virus (RSV) antigen refers to any substance, such as a protein or carbohydrate, that is found on the surface of the RSV virus and is recognized by the immune system as foreign. RSV antigens are used in the development of diagnostic tests, such as rapid antigen tests, to detect the presence of the virus in respiratory samples. Antigens are also used in the development of RSV vaccines, which aim to stimulate the immune system to produce an effective immune response against the virus. The identification and characterization of RSV antigens is important for understanding the biology of the virus and for the development of new and effective therapies against RSV.

The human respiratory syncytial virus (RSV) genome is a single-stranded RNA molecule that encodes the genetic information necessary for the replication and survival of the virus. The RSV genome is approximately 15 kb in length and is composed of 10 gene segments that encode for the virus’s structural and nonstructural proteins. The genetic information contained in the RSV genome is used by the virus to replicate and spread throughout the body, causing respiratory infections in humans. Understanding the structure and function of the RSV genome is important for the development of new diagnostic tools, treatments, and vaccines for RSV. The study of the RSV genome also provides important insights into the evolution and diversity of respiratory viruses and the mechanisms by which they cause disease.

The virus contains several important proteins, including the nucleocapsid protein, complete genome 9320, and major surface glycoprotein G.

The nucleocapsid protein is a structural protein that binds to the viral RNA genome and forms the core of the virus particle. The complete genome 9320 is the full sequence of the RSV genome, which contains all the genetic information necessary for the virus to replicate and cause infection. The major surface glycoprotein G is a key protein that allows the virus to attach to and enter host cells, making it an important target for vaccine development.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.